Amyloid Brain PET study

Phase 1

Recruiting

• Conditions: Dementia; D003704

• Registration Number: JPRN-jRCTs032230491
• Lead Sponsor: Takahashi Miwako

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2023-12-04
• Last Update Posted: 22 January 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 20

Inclusion Criteria

1. Patients who complained of subjective cognitive decline and visited a neurologist due to memory impairment and was suspected to be in the early stages of Alzheimer's disease according to the symptoms.
2. Age at the time of informed consent is 40 to 80 years old, regardless of gender.
3. Patients who had a score of 24 points or higher on MMSE conducted within 6 months before consent was obtained.
4. Patients who are judged by the principal investigator to be capable of understanding the study explanation and consent document.

Exclusion Criteria

1. History of hypersensitivity to alcohol.
2. History of serious complications, medical or surgery.
3. Patients currently taking medications; narcotics, psychotropic drugs, or anti-Parkinson's drugs.
4. Taking medications for diabetes mellitus.
5. Claustrophobia.
6. People who have difficulty undergoing head MRI due to tattoos (including tattoos and permanent makeup), pacemakers, cochlear implants, etc.
7.Patients who are pregnant or may be pregnant, or who are breastfeeding.
8.Patient who is judged to be inappropriate as a participant by the principal or collaborating doctors

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
1. Comparison of mean cortical SUVR of amyloid PET using a brain-dedicated PET and a whole-body PET <br>2. Characteristics of Abeta and FDG brain distribution in amyloid PET positive cases.

Secondary Outcome Measures

Name	Time	Method
Abeta mean cortical SUVR by Amyloid PET, FDG SUV by FDG-PET for each brain region.